Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28025688 | 0.96 | PSEN1 (0.49) | HTTPOLBGAAKMT2APSEN1 | |
| SCHEMBL28206454 | 0.91 | HTT (0.48) | HTTPOLBGAAKMT2ACRBN | |
| SCHEMBL6104351 | 0.80 | PSEN1 (0.42) | POLBGAAPSEN1PSEN2APH1B | |
| SCHEMBL31296370 | 0.80 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5753552 | 0.80 | PSEN1 (0.42) | POLBGAAPSEN1PSEN2APH1B | |
| SCHEMBL7566103 | 0.80 | EED (0.53) | HTTPOLBGAAKMT2APSEN1 | |
| SCHEMBL5755963 | 0.80 | DDB1 (0.57) | POLBCRBN | |
| SCHEMBL19050136 | 0.80 | POLB (0.47) | POLBKMT2ACYP26A1CYP24A1 | |
| SCHEMBL11790743 | 0.78 | EPHX2 (0.50) | POLBKMT2ACYP26A1CYP24A1 | |
| Hydrochloric Acid SCHEMBL15650706 | 0.78 | DDB1 (0.55) | POLBCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485351-A4 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7015320-B2 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1485351-A2 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | Bristol-Myers Squibb Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040010139-A1 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003079975-A2 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010139-A1 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | MRPL21, LAS1L, OXA1L | HTT 3582/4885POLB 3482/4885GAA 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.